Larimar Therapeutics (LRMR) to Release Quarterly Earnings on Thursday

Larimar Therapeutics (NASDAQ:LRMR) is expected to be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Larimar Therapeutics to post earnings of ($0.31) per share for the quarter.

Larimar Therapeutics Price Performance

Shares of NASDAQ:LRMR opened at $2.65 on Wednesday. Larimar Therapeutics has a 1-year low of $2.52 and a 1-year high of $11.20. The company has a market capitalization of $169.09 million, a PE ratio of -2.30 and a beta of 0.99. The business has a fifty day moving average price of $3.40 and a 200-day moving average price of $5.58.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on LRMR shares. Truist Financial started coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a research report on Tuesday, November 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Larimar Therapeutics in a research report on Friday, January 24th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $20.13.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.